Cellcept
✅ Prevents organ rejection
✅ Enhances immune response
✅ Treats autoimmune diseases
✅ Reduces inflammation
✅ Improves transplant success
✓ Medically reviewed by Morgan Ellis — Pharmacy Researcher · 8 years experience · Last reviewed: May 2026
⚡ Quick Answer — What is Cellcept?
Cellcept is an oral capsule containing mycophenolate mofetil 500 mg — a selective inosine monophosphate dehydrogenase (IMPDH) inhibitor that depletes guanosine nucleotides in proliferating lymphocytes. First-line maintenance immunosuppression after kidney, heart, and liver transplant (combined with a calcineurin inhibitor and corticosteroid), and a key agent in lupus nephritis and other severe autoimmune disease. Standard transplant maintenance: 1 g twice daily on an empty stomach (1 hour before or 2 hours after food), adjusted to white-cell count. Mandatory pregnancy-prevention programme — mycophenolate is a known human teratogen. Mandatory contraception starts 4 weeks before treatment, throughout, and 6 weeks after stopping. Mandatory monitoring: weekly FBC for first month, then every 2 weeks for 2 months, then monthly — lifelong while on therapy. FDA black-box: serious infections, lymphoma, embryofetal toxicity.
📦 Every order is covered by our Reshipment Assurance Policy — if your parcel does not arrive within 20 business days, we reship it.
What Is Cellcept?
Cellcept is an oral capsule (also available as tablets and oral suspension) containing mycophenolate mofetil 500 mg. Mycophenolate mofetil is the prodrug of mycophenolic acid, a selective inhibitor of inosine monophosphate dehydrogenase type II (IMPDH2) — the rate-limiting enzyme in de novo guanosine nucleotide synthesis. Lymphocytes depend almost entirely on this pathway for guanosine, so they are selectively depleted while other cell types use the salvage pathway. Originally developed by Roche (brand name CellCept), now widely available as generic.
How Does Cellcept Work?
- Selective lymphocyte suppression — T and B cells lose the ability to proliferate, but other immune cells (macrophages, neutrophils) and non-immune cells are largely spared.
- Inhibits both arms of acquired immunity — T-cell-mediated cellular rejection AND antibody-mediated humoral rejection.
- Replaces older azathioprine in most modern transplant protocols — lower acute rejection rates without increasing serious infection.
- Synergistic with calcineurin inhibitors (tacrolimus, ciclosporin) and corticosteroids in standard triple-therapy maintenance regimens.
Uses and Indications
- Prevention of rejection after kidney, heart, and liver transplantation (with calcineurin inhibitor + corticosteroid)
- Off-label transplant uses: lung, pancreas, intestinal transplant maintenance
- Lupus nephritis (induction and maintenance) — comparable efficacy to cyclophosphamide with better side-effect profile
- Other severe autoimmune disease: systemic lupus erythematosus, vasculitis, autoimmune hepatitis, refractory myasthenia gravis, IgG4-related disease, severe atopic dermatitis
- Refractory uveitis and severe ocular inflammation under specialist ophthalmology supervision
Cellcept is not indicated as monotherapy for any solid tumour or haematological malignancy. The primary categories of use are transplant medicine and autoimmune disease.
Cellcept Dosage and How to Take
| Indication | Standard adult dose | Notes |
|---|---|---|
| Renal transplant maintenance | 1 g twice daily | Empty stomach. Start within 72 h post-transplant. |
| Cardiac transplant maintenance | 1.5 g twice daily | Higher dose because of heart-transplant rejection risk profile. |
| Hepatic transplant maintenance | 1.5 g twice daily | Adjusted to MPA trough levels and FBC. |
| Lupus nephritis (induction) | 1–1.5 g twice daily | For 6 months. Ramp up over 2–4 weeks for tolerability. |
| Lupus nephritis (maintenance) | 500 mg–1 g twice daily | Continued for years — specialist titration. |
| Severe atopic dermatitis (off-label) | 500 mg–1.5 g twice daily | Specialist dermatology — second-line after methotrexate / ciclosporin / dupilumab. |
How to Take Cellcept Properly
- Take on an empty stomach — 1 hour before or 2 hours after meals. Food reduces peak mycophenolic acid concentration by ~40%.
- Swallow whole. Do not crush, chew, or open the capsule — mycophenolate is teratogenic and the powder is a contact hazard for women of childbearing potential and during pregnancy.
- Mandatory FBC monitoring: weekly during the first month, every 2 weeks for the next 2 months, then monthly. Stop if absolute neutrophil count drops below 1.3 × 10^9/L.
- Hand washing: wash hands thoroughly after handling capsules. Pregnant or potentially pregnant women must NOT handle broken or opened capsules.
- Pregnancy-prevention programme: two negative pregnancy tests (the second performed 8–10 days after the first) before starting. Effective contraception throughout treatment AND for 6 weeks after stopping. Two methods preferred (condom + hormonal, or condom + IUD). Apply the same rule to male partners — condoms throughout treatment + 90 days after stopping.
- Vaccinations: live vaccines (MMR, varicella, yellow fever, BCG) are contraindicated during treatment. Inactivated vaccines (annual flu, COVID, pneumococcal) are recommended but response may be reduced.
- Do not stop without specialist instruction — abrupt withdrawal in transplant patients risks acute rejection.
- Missed dose: take as soon as remembered the same day. If next dose due, skip and resume normally. Do not double-dose.
Side Effects of Cellcept
Common (often early in treatment, usually settle):
- Diarrhoea, nausea, abdominal pain (40–55%) — the dominant tolerability issue
- Vomiting
- Headache
- Hypertension (often pre-existing in transplant patients)
- Tremor
- Hyperglycaemia
- Mild peripheral oedema
Important — trigger investigation or treatment hold:
- Neutropenia (drop in white-cell count) — typically responds to dose reduction or temporary hold
- Anaemia — usually mild; severe cases may need dose modification or transfusion
- Lymphopenia — raises infection risk; the drug is doing what it is supposed to but watch for opportunistic infection
- Serious infections — CMV, BK polyomavirus (kidney transplant nephropathy), Pneumocystis jirovecii, opportunistic fungal infection
- JC virus reactivation → progressive multifocal leukoencephalopathy (PML) — rare but documented; new neurological symptoms must be investigated immediately
- Lymphoma and skin cancer — long-term immunosuppression increases the risk of post-transplant lymphoproliferative disorder (EBV-driven), non-melanoma skin cancer, and other malignancies. Annual skin examination + sun protection mandatory
Rare: pulmonary fibrosis, pure red-cell aplasia, severe hypogammaglobulinaemia.
Warnings and Precautions
- Pregnancy: ABSOLUTELY CONTRAINDICATED. Mycophenolate is a known human teratogen. First-trimester exposure is associated with first-trimester pregnancy loss and severe congenital malformations (microtia, ear-canal atresia, cleft lip/palate, distal limb anomalies, cardiac, oesophageal, renal). Mandatory pregnancy-prevention programme as above.
- Breastfeeding: contraindicated — small amounts excreted in animal models, human safety not established.
- Live vaccines: contraindicated during treatment.
- Active serious infection: hold treatment under specialist guidance.
- Severe renal impairment (eGFR < 25): dose reduction may be needed; specialist supervision.
- Hepatic impairment: no specific dose adjustment but monitor LFTs.
- Older patients: increased risk of opportunistic infection and GI haemorrhage.
- Contact precaution: pregnant women should not handle broken or opened capsules; the contents are teratogenic by direct skin contact.
Drug Interactions
| Combine with | Effect | What to do |
|---|---|---|
| Antacids (Mg/Al), proton pump inhibitors | Reduced mycophenolic acid absorption | Take Cellcept 2 hours before or 4 hours after antacids. Use famotidine instead of PPIs where possible. |
| Cholestyramine, colestipol, sevelamer | Disrupt enterohepatic recirculation — drop mycophenolic acid AUC by ~40% | Avoid — transplant-rejection risk. |
| Aciclovir, valaciclovir, ganciclovir, valganciclovir | Both renally cleared — mutual accumulation in renal impairment | Standard combinations in transplant. Monitor for cytopenia. |
| Azathioprine | Combined bone-marrow suppression | Avoid combination — Cellcept replaces azathioprine in modern protocols. |
| Oral contraceptives | Mycophenolate may modestly reduce hormone levels, AND combined oral contraceptives are insufficient as the only contraception during pregnancy-prevention programme | Use barrier method PLUS a hormonal method, or barrier PLUS IUD. |
| Live vaccines (MMR, varicella, yellow fever, BCG) | Risk of disseminated vaccine-strain infection | Contraindicated. Use inactivated alternatives where available. Vaccinate household contacts as a buffer. |
| Probenecid | Reduces mycophenolate clearance | Caution — monitor for toxicity. |
Storage Instructions
- Store at room temperature, 15–30°C. Keep in original blister.
- Keep out of reach of children, pets, pregnant women.
- Return unused capsules to a pharmacy for incineration disposal.
Why order from MedsBase
Every batch is sourced from a WHO-GMP certified manufacturer. Orders are dispatched in plain, unbranded packaging from our fulfilment partners and covered by our Reshipment Assurance Policy: if a parcel does not arrive within 20 business days we send a free reshipment, no questions asked.
Related Medications
Other medications stocked alongside this product:
- Rapacan (sirolimus 1 mg)
- Siromus (sirolimus 1 mg)
- Imutrex (methotrexate 2.5/7.5/10 mg)
- Folitrax (methotrexate 2.5/7.5/10 mg)
- Endoxan (cyclophosphamide 50 mg)
Frequently Asked Questions
Why is Cellcept listed under Anti-Cancer?
Mycophenolate mofetil is primarily a transplant immunosuppressant and autoimmune therapy — it is not a first-line cancer drug. Some early-stage trials in lymphoma and other malignancies have been performed but mycophenolate is not standard oncology therapy. The current category placement appears to be a historical taxonomy issue.
How long does it take to work?
Mycophenolic acid begins suppressing lymphocyte proliferation within hours of the first dose. In transplant rejection prevention, it must be started before or within 72 h of transplantation. In autoimmune disease, clinical response is typically seen at 6–12 weeks; full response at 6 months.
Can I take Cellcept on a full stomach if it makes me nauseous?
Food reduces mycophenolic acid peak concentration by about 40% — in transplant patients this can compromise rejection prevention. Try splitting the dose to four times daily, anti-nausea medication (ondansetron), or switching to enteric-coated mycophenolic sodium under specialist guidance. Discuss with your transplant team before changing dosing schedule.
Is mycophenolate teratogenic?
Yes — mycophenolate is a recognised human teratogen with a high rate of first-trimester pregnancy loss and severe congenital malformations (microtia, cleft lip/palate, cardiac defects, distal limb anomalies). The pregnancy-prevention programme is mandatory in every regulatory jurisdiction (FDA REMS in the US, EMA Pregnancy Prevention Programme in the EU). Two negative pregnancy tests before starting; effective contraception throughout treatment and for 6 weeks after stopping; condoms for male partners during treatment + 90 days after.
What infections are most common on Cellcept?
Most frequent are urinary tract infection, herpes simplex / zoster reactivation, and respiratory tract infections. More serious: CMV reactivation (especially in donor-positive / recipient-negative transplant), BK polyomavirus (kidney transplant nephropathy), Pneumocystis jirovecii pneumonia, EBV-driven post-transplant lymphoproliferative disorder. Most transplant centres use prophylactic valganciclovir, sulfamethoxazole-trimethoprim, and acyclovir.
Cellcept versus azathioprine — which is better?
Cellcept has largely replaced azathioprine in modern solid-organ transplant maintenance because it produces lower acute rejection rates without significantly increasing serious infection. Azathioprine remains useful in lupus, IBD, and where cost is a constraint. The two are not combined — both produce bone-marrow suppression.
Can I drink alcohol on Cellcept?
No specific alcohol interaction but moderation is sensible — alcohol worsens GI side effects (nausea, diarrhoea) and is contraindicated in many transplant indications because of liver and renal disease. If you take Cellcept for autoimmune disease, occasional moderate alcohol is generally acceptable but discuss with your specialist.
What happens if I stop Cellcept?
In transplant patients, abrupt cessation risks acute rejection within days — the calcineurin inhibitor and steroid are not always sufficient alone. Always taper or switch under transplant specialist guidance. In autoimmune disease, disease flare typically occurs within weeks to months.
Will Cellcept give me cancer?
Long-term immunosuppression increases the lifetime risk of certain malignancies: post-transplant lymphoproliferative disorder (EBV-driven, ~1–3% in first year post-transplant), non-melanoma skin cancer (annual examination, sun protection, SPF 50+), and a smaller increase in melanoma, anogenital, and Kaposi sarcoma. The risk is shared by all immunosuppressants, not specific to mycophenolate.
Are Cellcept and CellCept the same drug?
Yes — Cellcept (no internal capital) is the generic mycophenolate mofetil 500 mg formulation; CellCept (capital C) is the original Roche brand. Both contain the same active ingredient at identical doses with bioequivalent formulation.
Can I get vaccinated while on Cellcept?
Inactivated vaccines (annual influenza, COVID-19 mRNA, pneumococcal, hepatitis B, HPV, inactivated polio) are recommended — immune response is reduced but still meaningful. Live vaccines (MMR, varicella, yellow fever, BCG, oral typhoid, oral polio, intranasal flu) are contraindicated. Vaccinate household contacts as a protective buffer (they should not receive oral polio).
Medical disclaimer: This product page is for educational purposes and is not a substitute for medical advice. Immunosuppressants can cause life-threatening infections, malignancies, and birth defects. Use only under specialist supervision with appropriate monitoring.
More options in Anti Cancer Medication
Ranked by recent MedsBase order volume — what other customers in this category are picking.
| Strength | 500 mg |
|---|---|
| Quantity | 30 Capsule/s, 60 Capsule/s, 90 Capsule/s |
| Pharma Form | Capsule/s |
| Manufacturer | Roche Pharma |
| Treatment | Prevention of organ rejection in transplant patients |
| Generic Brand | Mycophenolate Mofetil |
Cellcept
Ερωτήσεις & Απαντήσεις
Cellcept
Σχετικά προϊόντα
Κριτικές
Δεν υπάρχουν ακόμη κριτικές